Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.43 |
| ▸ | GPR6 | P46095 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6458364 | 0.90 | KDM4E (0.46) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6457581 | 0.87 | KDM4E (0.48) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6467235 | 0.87 | LMNA (0.48) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6457769 | 0.86 | LMNA (0.46) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| Trifluoroacetic Acid SCHEMBL6461174 | 0.78 | SMN1; SMN2 (0.49) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6465690 | 0.77 | ADRA2A (0.66) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6465697 | 0.77 | ADRA2A (0.66) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| Hydrochloric Acid SCHEMBL6456895 | 0.76 | ADRA2A (0.65) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| Hydrochloric Acid SCHEMBL6456904 | 0.76 | ADRA2A (0.65) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A | |
| SCHEMBL6467255 | 0.74 | SMN1; SMN2 (0.51) | KDM4ELMNASMN1; SMN2MCHR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KDM4E 1190/4885LMNA 3391/4885SMN1; SMN2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.